Biosimilars have opened up access to expensive but lifesaving biologics in recent years, but some payer organizations, providers, and regulatory agencies have reservations about them. Real-world evidence (RWE) has the potential to accelerate uptake of biosimilars. In a new interview with Delphine Courmier of Organon, learn more about the importance of RWE for biosimilar adoption.
According to Courmier, “Biosimilars are still at the beginning of their journey in many countries, notably in the US. We learned from Europe that experience gained through real-life use and robust data collected in real-world evidence settings has played a major role to support adoption by addressing questions and concerns from payers, healthcare providers, physicians, and patients. This is essential because the promise of biosimilars – to deliver savings that support healthcare systems and can potentially get reinvested into unmet needs in patient care – can only be realized if biosimilars are widely adopted.”
To read more, click here.
(Source: The Evidence Base, June 6th, 2023)